In Vitro and In Vivo Efficacy and Tolerability of a Non-Hydroquinone, Multi-Action Skin Tone Correcting Cream

July 2019 | Volume 18 | Issue 7 | Original Article | 642 | Copyright © July 2019

Pearl E. Grimes MD,a David H. McDaniel MD,b Mitchell Wortzman PhD,c Diane Nelson RN MPHc

aVitiligo & Pigmentation Institute of Southern California, Los Angeles, CA

bMcDaniel Institute of Anti-Aging Research, Virginia Beach, VA

cskinbetter science LLC, Phoenix, AZ 

the overall quality of skin. This new, non-hydroquinone skin tone correcting cream represents an effective, non-irritating treatment option for patients with photodamage seeking to reduce the appearance of hyperpigmentation and improve the overall quality of their skin.


Pearl E. Grimes, MD: Director, Vitiligo and Pigmentation Institute of Southern California; Division of Dermatology, David Geffen School of Medicine, UCLA, Los Angeles, CA: Investigator for skinbetter science. David H. McDaniel, MD: Director, McDaniel Institute of Anti-Aging Research and McDaniel Laser and Cosmetic Center; Co-Director, Hampton University Skin of Color Research Institute, Hampton, VA; Adjunct Professor, School of Science, Hampton University, Hampton, VA; Adjunct Assistant Professor, Old Dominion University, Department of Biological Sciences, Norfolk, VA: Investigator and Consultant for skinbetter science. Mitchell Wortzman, PhD: Employee of skinbetter science. Diane B. Nelson, RN, MPH: Employee of skinbetter science.


We would like to thank Lynne Kolton Schneider, PhD, for her editorial assistance on this manuscript.


  1. Kang SJ, Davis SA, Feldman SR, McMichael AJ. Dyschromia in skin of color. J Drugs Dermatol. 2014;13(4):401-406.
  2. Vashi NA, Kundu RV. Facial hyperpigmentation: causes and treatment. Br J Dermatol. 2013;169 Suppl 3:41-56.
  3. Konda S, Geria AN, Halder RM. New horizons in treating disorders of hyperpigmentation in skin of color. Semin Cutan Med Surg. 2012;31(2):133-139.
  4. Abe Y, Takabe W, Yagi M, et al. Melanin synthesis induction by advanced glycation end-products (AGEs) without α-melanocyte stimulating hormone (α-MSH) or UV exposure. Glycative Stres Res. 2016;3(4):229-235.
  5. Barsh GS. What controls variation in human skin color? PLoS Biology. 2003;1(1):e27.
  6. Bastonini E, Kovacs D, Picardo M. Skin pigmentation and pigmentary disorders: focus on epidermal/dermal cross-talk. Ann Dermatol. 2016;28(3):279- 289;
  7. D’Mello SA, Finlay GJ, Baguley BC, Askarian-Amiri ME. Signaling pathways in melanogenesis. Int J Mol Sci. 2016;17(7).
  8. Videira IFdS, Magina S, Moura DFL. Mechanisms regulating melanogenesis. An Bras Dermatol. 2013;88(1):76-83.
  9. Kolbe L, Mann T, Gerwat W, et al. 4-n-butylresorcinol, a highly effective tyrosinase inhibitor for the topical treatment of hyperpigmentation. J Eur Acad Dermatol Venereol. 2013;27 Suppl 1:19-23.
  10. Davis EC, Callender VD. Postinflammatory hyperpigmentation: a review of the epidemiology, clinical features, and treatment options in skin of color. J Clin Aesthet Dermatol. 2010;3(7):20-31.
  11. Plensdorf S, Martinez J. Common pigmentation disorders. Am Fam Physician. 2009;79(2):109-116.
  12. Guerrero D. Dermocosmetic management of hyperpigmentations. Ann Dermatol Venereol. 2012;139 Suppl 4:S166-S169.
  13. Woolery-Lloyd H, Kammer JN. Treatment of hyperpigmentation. Semin Cutan Med Surg. 2011;30(3):171-175.
  14. Halder RM, Richards GM. Topical agents used in the management of hyperpigmentation. Skin Ther Lett. 2004;9(6):1-3.
  15. Sofen B, Prado G, Emer J. Melasma and post inflammatory hyperpigmentation: Management update and expert opinion. Skin Therapy Lett. 2016;21(1):1-7.
  16. Inoue Y, Hasegawa S, Yamada T, et al. Analysis of the effects of hydroquinone and arbutin on the differentiation of melanocytes. Biol Pharm Bull. 2013
  17. McDaniel DH, Mazur C, Wortzman MS, Nelson DB. Efficacy and tolerability of a double-conjugated retinoid cream vs 1.0% retinol cream or 0.025% tretinoin cream in subjects with mild to severe photoaging. J Cosmet Dermatol. 2017 Dec;16(4):542-548.
  18. Thornfeldt C, Rizer RL, Trookman NS. Blockade of melanin synthesis, activation and distribution pathway by a nonprescription natural regimen is equally effective to a multiple prescription-based therapeutic regimen. J Drugs Dermatol. 2013;12(12):1448-1454.
  19. Grimes PE. An efficacy study of 3 commercially available hydroquinone 4% treatments for melasma. Cutis. 2007;80:497-502.
  20. Draelos ZD, Yatskayer M, Bhushan P, Pillai S, Oresajo C. Evaluation of a kojic acid, emblica extract, and glycolic acid formulation compared with hydroquinone 4% for skin lightening. Cutis. 2010;86(3):153-158.
  21. Draelos ZD. Skin lightening preparations and the hydroquinone controversy. Dermatol Ther. 2007;20(5):308-313.
  22. Fisk WA, Agbai O, Lev-Tov HA, Sivamani RK. The use of botanically derived agents for hyperpigmentation: a systematic review. J Am Acad Dermatol. 2014;70(2):352-365.
  23. Bruce S. Safety and efficacy of a novel multimodality hydroquinone-free skin brightener over six months. J Drugs Dermatol. 2013;12(3):S27-S31.
  24. Fabi SG, Goldman MP. Comparative study of hydroquinone-free and hydroquinone-based hyperpigmentation regimens in treating facial hyperpigmentation and photoaging. J Drugs Dermatol. 2013;12(3):S32-S37.
  25. Farris P, Zeichner J, Berson D. Efficacy and tolerability of a skin brightening/ anti-aging cosmeceutical containing retinol 0.5%, niacinamide, hexylresorcinol, and resveratrol. J Drugs Dermatol. 2016;15(7):863-868.
  26. Foad MS, Winters E. Hydroquinone-free multimodal topical regimen for facial hyperpigmentation. J Drugs Dermatol. 2013;12(3 Suppl 1):S42-S44.
  27. Gold MH, Biron J. Efficacy of a novel hydroquinone-free skin-brightening cream in patients with melasma. J Cosmet Dermatol. 2011;10(3):187-196.
  28. Jung YS, Lee JH, Bae JM, Lee DW, Kim GM. Assessment of the efficacy and safety of a new complex skin cream in Asian women: a controlled clinical trial. J Cosmet Dermatol. 2017;16(2):253-257


Diane Nelson RN MPH